WO2017142254A1 - 발모 및/또는 육모 촉진 활성을 나타내는 펩타이드 및 이의 용도 - Google Patents
발모 및/또는 육모 촉진 활성을 나타내는 펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- WO2017142254A1 WO2017142254A1 PCT/KR2017/001409 KR2017001409W WO2017142254A1 WO 2017142254 A1 WO2017142254 A1 WO 2017142254A1 KR 2017001409 W KR2017001409 W KR 2017001409W WO 2017142254 A1 WO2017142254 A1 WO 2017142254A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- hair
- hair growth
- expression
- growth
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 123
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 title claims abstract description 9
- 210000004209 hair Anatomy 0.000 title abstract description 24
- 230000003779 hair growth Effects 0.000 claims abstract description 80
- 201000004384 Alopecia Diseases 0.000 claims abstract description 24
- 230000001737 promoting effect Effects 0.000 claims abstract description 22
- 208000024963 hair loss Diseases 0.000 claims abstract description 20
- 239000003102 growth factor Substances 0.000 claims abstract description 8
- 230000003752 improving hair Effects 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 11
- 102000015735 Beta-catenin Human genes 0.000 claims description 10
- 108060000903 Beta-catenin Proteins 0.000 claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 108091007960 PI3Ks Proteins 0.000 claims description 10
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 10
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 8
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 8
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 8
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 8
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 claims description 8
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 claims description 8
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 7
- 108700000707 bcl-2-Associated X Proteins 0.000 claims description 7
- 102000055102 bcl-2-Associated X Human genes 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 108010066321 Keratin-14 Proteins 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 210000000442 hair follicle cell Anatomy 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102000018332 Keratin-14 Human genes 0.000 claims 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 16
- 230000003676 hair loss Effects 0.000 abstract description 15
- 230000012010 growth Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000003325 follicular Effects 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 230000002500 effect on skin Effects 0.000 description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 13
- 210000003780 hair follicle Anatomy 0.000 description 11
- -1 pack Substances 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010805 cDNA synthesis kit Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000011191 terminal modification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide that exhibits hair growth and / or hair growth promoting activity, a composition for promoting hair growth comprising the peptide as an active ingredient, and a hair growth promoting use of the peptide.
- Hair follicles are unique organs of mammalian skin, with the lower part of the primitive epidermis growing and extending into the deeper skin layers.
- the base of the hair follicle, the plug of the cell known as follicle or dermal papilla cells are present, and... (Stenn and Paus, Physiol Rev., 81:. 449 (2002)) teats normal circulation (Oliver, Embryol Exp Morph 15 of the follicular : 3311 (1966); Oliver, Embryol . Exp . Morph. 16: 231 (1966)) and hair shaft growth.
- the hair shaft is a tread-shaped structure made of tightly adherent epithelial cells filled with keratin filaments and filament aggregate proteins.
- hair loss spreads.
- different disease states such as scarring alopecia, scarring conditions associated with burns or compression injuries can cause significant hair loss.
- various substances have been used as a medicine until now, but the price is too expensive and various side effects are caused.
- the raw materials used in cosmetics have the advantage of low price, but since the composition is composed of plant-derived ingredients, the effect is not so great. Therefore, there is a need in the art for a new effective ingredient that is both economical and cost effective.
- dihydrotestosterone is added by adding a composition containing extracts such as red ginseng, red pepper, sugar, lettuce, green leaf, lettuce, licorice, licorice, peony, turmeric, fennel, cornus and garlic, and a composition containing xanthine and growth hormone.
- a composition containing extracts such as red ginseng, red pepper, sugar, lettuce, green leaf, lettuce, licorice, licorice, peony, turmeric, fennel, cornus and garlic
- a composition containing xanthine and growth hormone In order to improve the inhibition of cellular metabolism due to the excessive amount of growth hormone, growth hormone promotes hair growth, prevents hair loss and regenerates hair, and promotes hair growth, minerals, vitamins, and green tea to promote hair growth.
- the inventors have selected three peptides showing excellent hair growth efficacy from the peptide library of the present inventors, and have experimented on their hair growth and / or hair growth efficacy. By clarifying, the present invention has been completed.
- a peptide that exhibits hair growth and / or hair growth promoting activity consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs.
- Another object of the present invention is to provide a composition for preventing and / or improving hair loss comprising at least one peptide selected from the group consisting of peptides consisting of amino acid sequences selected from the group consisting of SEQ ID NOs.
- Still another object of the present invention is to provide a composition for promoting hair growth and / or hair growth comprising at least one peptide selected from the group consisting of peptides consisting of amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 3 as an active ingredient. .
- Still another object of the present invention is to provide a use for preventing and / or improving hair loss of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs.
- Still another object of the present invention is to provide a hair growth and / or hair growth promoting use of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs.
- the inventors have selected three peptides showing excellent hair growth and / or hair growth promoting effects from our peptide library, and their hair growth and / or The hair growth promoting effect was experimentally identified.
- One aspect of the invention relates to a peptide exhibiting hair growth and / or hair growth promoting activity comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 3.
- the peptide may be an amino acid sequence consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 3, for example, may be composed of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 3.
- peptide refers to a linear molecule formed by binding amino acid residues to each other by peptide bonds.
- Peptides of the invention are known in the art for chemical synthesis methods, in particular solid-phase synthesis techniques; Merrifield, J. Amer . Chem . Soc . 85: 2149-54 (1963); Stewart, et al., Solid Phase Peptide Synthesis , 2nd. Ed., Pierce Chem. Co .: Rockford, 111 (1984)) or liquid phase synthesis technology (US Pat. No. 5,516,891).
- Peptides of the present invention are screened peptides excellent in hair growth through cell proliferation experiments among the peptide library possessed by the present inventors, a total of three kinds are provided as peptides of the present invention.
- the peptides of the invention can induce N-terminal and / or C-terminal modifications of the peptides to select some sites of the amino acid sequence and increase their activity.
- the C-terminal modification may be one in which the C-terminal of the peptide is modified with a hydroxyl group (-OH), an amino group (-NH 2 ), an azide (-NHNH 2 ), and the like, but is not limited thereto.
- the N-terminal modification is 1 wherein the N-terminal of the peptide is selected from the group consisting of acetyl group, fluorenyl methoxy carbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group and polyethylene glycol (PEG)
- One or more protecting groups may be combined, but is not limited thereto.
- the protecting group serves to protect the peptide of the present invention from the attack of protein cleavage enzymes in vivo.
- the N-terminal and / or C-terminal modification of the peptide acts to greatly improve the stability of the peptide.
- the peptide of the present invention may have a high half-life by increasing the half-life when administered in vivo.
- stability herein means not only in vivo stability but also storage stability (eg, room temperature storage stability).
- hair growth promotion means that the hair is produced, it is used in a broad sense to increase the hair production rate and production amount. In addition, it means that the hair root function is enhanced, or the hair dropping and production cycle is shortened, thereby increasing the number of hairs growing in the hair follicles.
- hair growth or “hair growth” means that the thickness of the generated hair (hair) is increased or affects the growth rate of the length.
- the peptide of the present invention promotes the growth of hair follicle cells, increases the expression of ⁇ -catenin, a hair growth related factor, and KGF (Keratinocyte growth factor), a hair growth related growth factor, bFGF ( Increases the expression of Basic fibroblast growth factor (VGF), Vascular endothelial growth factor (VEGF), increases expression of the hair growth signaling molecule, Phosphoinositide 3-kinase (PI3K), and increases phosphorylation of extracellular signal-regulated kinase (ERK), Increases the expression of MSX2 and caratin-14, a hair growth-related factor, inhibits the expression of TGF- ⁇ 1 associated with hair growth retardation, and increases the expression of Bcl-2, an apoptosis inhibiting protein, and apoptosis-related protein Bax. Induces a decrease in expression.
- KGF Keratinocyte growth factor
- bFGF Increases the expression of Basic fibroblast growth factor (VGF)
- the peptides of the present invention have very good efficacy against hair growth and / or hair growth. Therefore, the peptide of the present invention can be used for preventing and / or improving hair loss, promoting hair growth and / or hair growth.
- Another aspect of the invention relates to a composition for preventing or improving hair loss comprising the peptide of the present invention as an active ingredient.
- anti-hair loss means that the phenomenon of hair dropout in hair follicles or scalp is prevented or weakened.
- the peptide of the present invention induces the proliferation of cells in the hair follicle of the skin tissue, which enables the production of hair roots, thereby allowing the production of new hair follicles. Furthermore, it activates the beta-catenin signal to express hair growth promoting genes and increases the expression of growth factors involved in hair growth.
- the peptide of the present invention serves to promote the growth stage, which is the time at which hair is produced and grown, and exhibits hair loss inhibiting effect by maintaining the cycle of the hair that progresses to the regenerator due to various environmental factors, and in normal hair, hair Nourishes your hair to keep it healthy. Therefore, the composition of the present invention is very effective in preventing and / or improving hair loss.
- composition of the present invention includes the above-described peptide of the present invention as an active ingredient, the common content between the two is omitted in order to avoid excessive complexity of the present specification.
- compositions for promoting hair growth and / or hair growth comprising at least one peptide selected from the group consisting of peptides consisting of amino acid sequences selected from the group consisting of SEQ ID NO: 1 to 3 as an active ingredient. .
- composition of the present invention may be prepared as a cosmetic composition, but is not limited thereto.
- the cosmetic composition may include a cosmetically effective amount of the above-described peptide of the present invention.
- the cosmetic composition may further include a cosmetically acceptable carrier, but is not limited thereto.
- cosmetic effective amount means an amount sufficient to achieve the efficacy of the cosmetic composition of the present invention described above.
- Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and / or sprays, and the like, but are not limited thereto.
- it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and / or powder.
- the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components. It may be, but is not limited thereto.
- the formulation of the cosmetic composition is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of a spray, additionally chlorofluorohydrocarbon, Propellants such as propane / butane or dimethyl ether may be included, but are not limited thereto.
- a solvent, a solubilizer or an emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, Fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- a liquid diluent such as water, ethanol or propylene glycol
- a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester as a carrier component
- Crystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant may be used, but is not limited thereto.
- the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid.
- Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters may be used, but are not limited thereto.
- Components included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions, in addition to peptides and carrier components as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments And / or conventional adjuvants such as flavorings.
- Another aspect of the invention relates to the use of preventing and / or ameliorating hair loss of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs.
- Another aspect of the present invention relates to the use of the peptides consisting of amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 3 to promote hair growth and / or hair growth.
- the present invention provides a peptide having hair growth and / or hair growth promoting activity, a composition for preventing and / or improving hair loss comprising the peptide as an active ingredient, a composition for promoting hair growth and / or hair growth comprising the peptide as an active ingredient, and the peptide
- a composition for promoting hair growth and / or hair growth comprising the peptide as an active ingredient
- the peptide to prevent and / or ameliorate hair loss, and to promote hair growth and / or hair growth of the peptide, wherein the peptide promotes hair follicle cell growth and increases the expression of hair growth-related growth factors and hair growth-related factors. Or it shows an excellent effect on hair growth, it can be very advantageously applied to cosmetics by excellent activity and stability.
- 1A is a graph showing the growth promoting effect of human hair follicle dermal papilla cells (HHFDPC) of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- HHFDPC human hair follicle dermal papilla cells
- Figure 1b is a graph showing the effect of promoting the growth of human hair follicle dermal papilla cells (HHFDPC) of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- HHFDPC human hair follicle dermal papilla cells
- 1C is a graph showing the growth promoting effect of human hair follicle dermal papilla cells (HHFDPC) of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- HHFDPC human hair follicle dermal papilla cells
- Figure 2a is a figure showing the results confirmed that the expression of ⁇ -catenin is increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 2b is a view showing the results confirmed that the expression of ⁇ -catenin is increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 2c is a view showing the result of confirming that the expression of ⁇ -catenin is increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 3a is a photograph showing the results of confirming the increase in expression of KGF, bFGF by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 3b is a view showing the result of confirming the increase in expression of VEGF by the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 3c is a view showing the results of confirming the expression of VEGF, bFGF increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 4a is a photograph showing the results of confirming the increase in PI3K expression and ERK phosphorylation by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 4b is a picture showing the results confirmed the increase in PI3K expression and ERK phosphorylation by the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 4c is a picture showing the results confirmed the increase in PI3K expression and ERK phosphorylation by the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 5a is a photograph showing the result of confirming the increase in the expression of MSX2 by the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 5b is a photograph showing the result of confirming the increase in the expression of MSX2 by the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 6a is a photograph showing the results of confirming the inhibition of TGF- ⁇ 1 expression by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 6b is a photograph showing the results of confirming the inhibition of TGF- ⁇ 1 expression by the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 7a is a photograph showing the results of confirming the increase in the expression of Bcl-2 and reduced Bax expression by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 7b is a photograph showing the results of confirming the increased expression of Bcl-2 and reduced Bax expression by the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 8 is a photograph showing the result of confirming the increase in the expression of keratin-14 by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- peptide exhibiting hair growth promoting activity consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 3.
- chloro trityl chloride resin CTL resin, Nova biochem Cat No. 01-64-0021
- MC methylene chloride
- DMF dimethylformamide
- 10 ml of dichloromethane solution was added to the reactor, 200 mmole of Fmoc-Ile-OH (Bachem, Swiss) and 400 mmole of diisopropyl ethylamine (DIEA) were added thereto, stirred to dissolve well, and reacted with stirring for 1 hour.
- the Fmoc-protector was reacted twice with a deprotection solution twice for 10 minutes and then washed well.
- acetic anhydride, DIEA, and HoBt were added to acetylate for one hour
- the prepared peptidyl resin was washed three times with DMF, MC, and methanol, and dried slowly by flowing nitrogen air, followed by P 2 O 5
- a fugitive solution Trifluroacetic acid 95%, distilled water 2.5%, Thianisole 2.5%), and then shake at room temperature for 2 hours. Maintained.
- the resin was filtered off and the resin was washed with a small amount of TFA solution and then combined with the mother liquor.
- Peptide 2 consisting of the amino acid sequence of SEQ ID NO: 2 and other peptides peptide 3 consisting of the amino acid sequence of SEQ ID NO: 3 was also synthesized in the same manner as above.
- Human hair follicle dermal papilla cells were seeded in 96-well plates at a density of 2 ⁇ 10 3 cells / well and cultured overnight. After changing to serum-free medium, the peptides were treated and incubated for 3 days, and 100 mg of 4 mg / ml MTT solution were treated in wells for 4 hours. After the resulting formazan was dissolved through DMSO treatment, the absorbance at 560 nm was measured using a microplate reader, and the results are shown in FIGS. 1A to 1C.
- Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated and cultured for 15 and 30 minutes, and cells were recovered to separate nuclear and cytoplasmic proteins, respectively. Western blotting was performed using a ⁇ -catenin antibody (santacruz biotechnology, USA) to compare the expression of ⁇ -catenin in the nucleus, and the results are shown in FIGS. 2A to 2C.
- nuclear translocation according to the increase of the activity of ⁇ -catenin, a hair growth-related factor in human dermal papilla cells consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 It was observed to be promoted by peptide treatment.
- Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated, incubated for 24 hours, and cells were recovered to separate RNA. After quantifying RNA, cDNA was synthesized using cDNA synthesis kit (Intron, Korea), PCR was performed using PCR premix (Intron, Korea) and primers of KGF, bFGF, and VEGF, followed by electrophoresis on 5% agarose gel. Comparison of the mRNA expression level of the growth factors in the sample treatment conditions, the results are shown in Figures 3a to 3c.
- Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, the peptide was treated and cultured for 15 and 30 minutes, and the cells were recovered to prepare cell lysates. Western blotting was performed using a PI3K antibody (santacruz biotechnology, USA) and a phospho-ERK antibody (Cell Signaling Technology, USA) to compare protein expression patterns, and the results are shown in FIGS. 4A and 4B.
- Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated, incubated for 24 hours, and cells were recovered to separate RNA. After quantifying RNA, cDNA was synthesized using cDNA synthesis kit (Intron, Korea), and PCR was performed using PCR premix (Intron, Korea) and MSX2 primer, followed by electrophoresis on 5% agarose gel to express mRNA under each sample treatment condition. The degree is compared and the result is shown to FIG. 5A and 5B.
- RNA samples Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated, incubated for 24 hours, and cells were recovered to separate RNA. After quantification of RNA, cDNA was synthesized using cDNA synthesis kit (Intron, Korea), PCR was performed using PCR premix (Intron, Korea) and TGF- ⁇ 1 primer, followed by electrophoresis on 5% agarose gel in each sample processing condition. The degree of mRNA expression was compared, and the results are shown in FIGS. 6A and 6B.
- Human dermal papilla cells were seeded in 6-well plates at a density of 4 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated, cultured for 24 hours, and cells were recovered to prepare cell lysates. Western blots were performed using Bcl-2 and Bax antibodies (santacruz biotechnology, USA) to compare protein expression patterns, and the results are shown in FIGS. 7A and 7B.
- RNA samples Human dermal papilla cells were seeded in 6-well plates at a density of 5 ⁇ 10 5 cells / well and cultured overnight. After changing to serum-free medium, peptides were treated, incubated for 24 hours, and cells were recovered to separate RNA. After quantification of RNA, cDNA was synthesized using cDNA synthesis kit (Intron, Korea), PCR was performed using PCR premix (Intron, Korea) and keratin-14 primer, followed by electrophoresis on 5% agarose gel under each sample treatment condition. The degree of mRNA expression was compared, and the results are shown in FIG. 8.
- the present invention relates to a peptide that exhibits hair growth and / or hair growth promoting activity, a composition for promoting hair growth comprising the peptide as an active ingredient, and a hair growth promoting use of the peptide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
서열번호 | 서열목록 (5'->3') | 분자량 분석값(질량분석기) | |
분석치 | 이론치 | ||
1 | Arg-Arg-Lys-Ile | 571.7 | 571.72 |
2 | Ile-Tyr-Phe-Tyr | 604 | 604.7 |
3 | Lys-Lys-Phe-Ile-Gln-Gln-Val-Tyr-Leu-Ala-Ile | 1350.6 | 1350.65 |
서열번호 | 프라이머 명명 | 서열목록(5'-3') |
4 | KGF_F | TCTGTCGAACACAGTGGTACCT |
5 | KGF_R | GTGTGTCCATTTAGCTGATGCAT |
6 | bFGF_F | TGCTGGTGATGGGAGTTGTA |
7 | bFGF_R | CCTCCAAGTAGCAGCCAAAG |
8 | VEGF_F | CCATGAACTTTCTGCTGTCTT |
9 | VEGF_R | TCGATCGTTCTGTATCAGTCT |
서열번호 | 프라이머 명명 | 서열목록(5'-3') |
10 | MSX2_F | AACACAAGACCAACCGGAAG |
11 | MSX2_R | GCAGCCATTTTCAGCTTTTC |
서열번호 | 프라이머 명명 | 서열목록(5'-3') |
12 | TGF-β1_F | GCCCTGGATACCAACTATTGC |
13 | TGF-β1_R | TCAGCACTTGCAGGAGTAGCG |
서열번호 | 프라이머 명명 | 서열목록(5'-3') |
14 | Keratin-14_F | CCACCTTTCATCTTCCCAATTCTC |
15 | Keratin-14_R | GTGCGGATCTGGCGGTTG |
Claims (10)
- 서열번호 1 내지 3으로 이루어진 군에서 선택된 아미노산 서열로 이루어진 발모 촉진 활성을 나타내는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 모낭 세포 성장을 촉진하는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 β-카테닌의 발현을 증가시키는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 KGF(Keratinocyte Growth Factor), bFGF(Basic fibroblast growth factor) 및 VEGF(Vascular endothelial growth factor)로 이루어진 군으로부터 선택되는 발모 관련 성장인자의 발현을 증가시키는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 MSX2(Msh homeobox 2) 및 케라틴-14로 이루어진 군으로부터 선택되는 발모 관련 인자의 발현을 증가시키는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 PI3K(Phosphoinositide 3-kinase)의 발현 및 ERK(Extracellular Signal-regulated Kinase) 인산화를 증가시키는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 TGF-β1(transforming growth factor beta 1)의 발현을 억제하는 것을 특징으로 하는 펩타이드.
- 제1항에 있어서, 상기 펩타이드는 Bcl-2(B-cell lymphoma 2)의 발현을 증가시키고 Bax(BCL2-associated X protein)의 발현을 감소시키는 것을 특징으로 하는 펩타이드.
- 서열번호 1 내지 3으로 이루어진 군에서 선택된 아미노산 서열로 이루어진 펩타이드로 이루어진 군에서 선택된 1종 이상의 펩타이드를 유효성분으로 포함하는 탈모 방지 또는 개선용 조성물.
- 서열번호 1 내지 3으로 이루어진 군에서 선택된 아미노산 서열로 이루어진 펩타이드로 이루어진 군에서 선택된 1종 이상의 펩타이드를 유효성분으로 포함하는 발모 또는 육모 촉진용 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780010329.8A CN108699109B (zh) | 2016-02-18 | 2017-02-09 | 呈现生发和/或育发促进活性的肽及其的用途 |
US15/999,744 US10568828B2 (en) | 2016-02-18 | 2017-02-09 | Peptide having hair growth-promoting activity and use thereof |
ES17753415T ES2870470T3 (es) | 2016-02-18 | 2017-02-09 | Péptido que tiene actividad promotora del crecimiento del cabello y uso del mismo |
CN202210942015.4A CN116333044A (zh) | 2016-02-18 | 2017-02-09 | 呈现生发和/或育发促进活性的肽及其的用途 |
JP2018560419A JP6672482B2 (ja) | 2016-02-18 | 2017-02-09 | 発毛及び/又は育毛促進活性を示すペプチド及びその用途 |
CN202210941330.5A CN116333039A (zh) | 2016-02-18 | 2017-02-09 | 呈现生发和/或育发促进活性的肽及其的用途 |
EP17753415.3A EP3418291B1 (en) | 2016-02-18 | 2017-02-09 | Peptide having hair growth-promoting activity and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160019292A KR101791526B1 (ko) | 2016-02-18 | 2016-02-18 | 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
KR10-2016-0019292 | 2016-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017142254A1 true WO2017142254A1 (ko) | 2017-08-24 |
Family
ID=59625213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/001409 WO2017142254A1 (ko) | 2016-02-18 | 2017-02-09 | 발모 및/또는 육모 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10568828B2 (ko) |
EP (1) | EP3418291B1 (ko) |
JP (3) | JP6672482B2 (ko) |
KR (1) | KR101791526B1 (ko) |
CN (3) | CN108699109B (ko) |
ES (1) | ES2870470T3 (ko) |
WO (1) | WO2017142254A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102069184B1 (ko) | 2019-06-28 | 2020-01-22 | (주)미래씨티 | 신경줄기세포 추출물유래 bmp신호전달경로 억제 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 발모촉진 또는 탈모방지 조성물 |
KR102265431B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
JP7485336B2 (ja) | 2020-04-01 | 2024-05-16 | 丸善製薬株式会社 | MSX-2 mRNA発現促進剤、まつ毛の育毛剤、及びまつ毛の育毛用外用剤組成物 |
KR20230047693A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20230047688A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20230047691A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20230047689A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20230047692A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20230047690A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR20240050563A (ko) * | 2022-10-11 | 2024-04-19 | (주)케어젠 | 발모 촉진 및 탈모 억제 활성을 갖는 펩타이드 및 이의 용도 |
KR20240050564A (ko) * | 2022-10-11 | 2024-04-19 | (주)케어젠 | 발모 촉진 및 탈모 억제 활성을 갖는 펩타이드 및 이의 용도 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516891A (en) | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
JP2005239695A (ja) * | 2004-02-27 | 2005-09-08 | Mitsui Chemicals Inc | TGF−β産生抑制ペプチド |
US7057013B1 (en) * | 1998-11-24 | 2006-06-06 | Proyecto De Biomedicina Cima, S.L. | TGFβ1 inhibitor peptides |
KR20130014700A (ko) * | 2011-07-26 | 2013-02-08 | 서울대학교산학협력단 | Vegf 발현을 증가시키는 신규한 펩타이드 및 이를 함유하는 약학적 조성물 |
KR20140107784A (ko) * | 2013-02-28 | 2014-09-05 | 주식회사 크라운진 | 탈모 방지 및 모발 성장 촉진용 조성물 |
KR20160003611A (ko) * | 2015-12-21 | 2016-01-11 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1226552B (it) * | 1988-07-29 | 1991-01-24 | Ellem Ind Farmaceutica | Peptidi immunostimolanti. |
GB9801191D0 (en) * | 1998-01-20 | 1998-03-18 | Unilever Plc | Skin and hair darkening composition |
US6696417B1 (en) | 1997-11-21 | 2004-02-24 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin and hair darkening composition |
WO2002006515A2 (en) * | 2000-07-17 | 2002-01-24 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
US20030060438A1 (en) * | 2000-08-18 | 2003-03-27 | Henry James L. | Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof |
WO2002022667A2 (en) * | 2000-09-18 | 2002-03-21 | Genencor International, Inc. | Twin-arginine translocation in bacillus |
FR2857667B1 (fr) * | 2003-07-18 | 2007-07-13 | Inst Europ Biolog Cellulaire | Nouveaux conjugues peptidiques utiles dans le traitement preventif et curatif de l'alopecie |
JPWO2005082395A1 (ja) * | 2004-03-02 | 2008-01-17 | 国立大学法人京都大学 | 新規な育毛剤、抗脱毛症剤 |
JP4461261B2 (ja) * | 2004-05-27 | 2010-05-12 | 国立大学法人京都大学 | 新規な育毛剤 |
JP4861686B2 (ja) * | 2005-11-17 | 2012-01-25 | ライオン株式会社 | 神経栄養因子−4(Neurotrophin−4)アンタゴニスト |
JP5048372B2 (ja) * | 2007-03-30 | 2012-10-17 | 日本サプリメント株式会社 | 育毛促進剤 |
KR101163171B1 (ko) * | 2009-01-20 | 2012-07-19 | (주)케어젠 | 노긴?유래 펩타이드 및 그의 용도 |
KR101187871B1 (ko) | 2009-09-23 | 2012-10-05 | (주)케어젠 | Fgf10-유래 펩타이드 및 그의 용도 |
KR101285263B1 (ko) * | 2011-08-04 | 2013-07-11 | (주)케어젠 | Edar 리간드 유래 펩타이드 및 이의 용도 |
KR101285259B1 (ko) * | 2011-08-04 | 2013-07-11 | (주)케어젠 | Wnt 계열 유래 펩타이드 및 이의 용도 |
KR101632948B1 (ko) | 2014-05-13 | 2016-06-27 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
KR101618329B1 (ko) | 2015-12-21 | 2016-05-19 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
KR101841748B1 (ko) * | 2016-02-18 | 2018-05-08 | (주)케어젠 | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
-
2016
- 2016-02-18 KR KR1020160019292A patent/KR101791526B1/ko active IP Right Grant
-
2017
- 2017-02-09 JP JP2018560419A patent/JP6672482B2/ja active Active
- 2017-02-09 ES ES17753415T patent/ES2870470T3/es active Active
- 2017-02-09 EP EP17753415.3A patent/EP3418291B1/en active Active
- 2017-02-09 CN CN201780010329.8A patent/CN108699109B/zh active Active
- 2017-02-09 US US15/999,744 patent/US10568828B2/en active Active
- 2017-02-09 CN CN202210941330.5A patent/CN116333039A/zh active Pending
- 2017-02-09 WO PCT/KR2017/001409 patent/WO2017142254A1/ko active Application Filing
- 2017-02-09 CN CN202210942015.4A patent/CN116333044A/zh active Pending
-
2020
- 2020-03-04 JP JP2020036395A patent/JP6866518B2/ja active Active
- 2020-03-04 JP JP2020036406A patent/JP6868723B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516891A (en) | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
US7057013B1 (en) * | 1998-11-24 | 2006-06-06 | Proyecto De Biomedicina Cima, S.L. | TGFβ1 inhibitor peptides |
JP2005239695A (ja) * | 2004-02-27 | 2005-09-08 | Mitsui Chemicals Inc | TGF−β産生抑制ペプチド |
KR20130014700A (ko) * | 2011-07-26 | 2013-02-08 | 서울대학교산학협력단 | Vegf 발현을 증가시키는 신규한 펩타이드 및 이를 함유하는 약학적 조성물 |
KR20140107784A (ko) * | 2013-02-28 | 2014-09-05 | 주식회사 크라운진 | 탈모 방지 및 모발 성장 촉진용 조성물 |
KR20160003611A (ko) * | 2015-12-21 | 2016-01-11 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
Non-Patent Citations (6)
Title |
---|
ARCK, PETRA CLARA; HANDJISKI, BORI, AMERICAN JOURNAL OF PATHOLOGY, vol. 162, no. 3, 2003 |
MERRIFIELD, J. AMER. CHEM. SOC., vol. 85, 1963, pages 2149 - 54 |
OLIVER, EMBRYOL. EXP. MORPH., vol. 15, 1966, pages 3311 |
OLIVER, EMBRYOL. EXP. MORPH., vol. 16, 1966, pages 231 |
STENN; PAUS, PHYSIOL. REV., vol. 81, 2002, pages 449 |
STEWART ET AL.: "Solid Phase Peptide Synthesis", 1984, PIERCE CHEM. CO. |
Also Published As
Publication number | Publication date |
---|---|
JP6672482B2 (ja) | 2020-03-25 |
CN116333044A (zh) | 2023-06-27 |
US10568828B2 (en) | 2020-02-25 |
KR20170097830A (ko) | 2017-08-29 |
EP3418291A1 (en) | 2018-12-26 |
CN108699109B (zh) | 2022-08-16 |
KR101791526B1 (ko) | 2017-11-01 |
EP3418291B1 (en) | 2021-03-24 |
CN116333039A (zh) | 2023-06-27 |
CN108699109A (zh) | 2018-10-23 |
JP2020105196A (ja) | 2020-07-09 |
JP6868723B2 (ja) | 2021-05-12 |
JP2020105197A (ja) | 2020-07-09 |
EP3418291A4 (en) | 2019-01-02 |
US20190046427A1 (en) | 2019-02-14 |
JP6866518B2 (ja) | 2021-04-28 |
ES2870470T3 (es) | 2021-10-27 |
JP2019507187A (ja) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017142254A1 (ko) | 발모 및/또는 육모 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
WO2017155232A2 (ko) | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
KR101285259B1 (ko) | Wnt 계열 유래 펩타이드 및 이의 용도 | |
KR101198918B1 (ko) | Wnt10?유래 펩타이드 및 그의 용도 | |
WO2017142305A1 (ko) | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
WO2018131900A2 (ko) | 나노그를 도입한 양수 내 태아 유래 중간엽 줄기세포로부터 획득한 엑소좀 내 포함된 육모 촉진용 조성물의 제조방법 | |
WO2017105161A2 (ko) | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 | |
EP2740740B1 (en) | Edar ligand-derived peptide and uses thereof | |
KR101810868B1 (ko) | 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
EP3431505B1 (en) | Conjugate of finasteride with peptide | |
EP3501545B1 (en) | Conjugate of minoxidil and peptide | |
WO2018199358A1 (ko) | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 | |
KR101885847B1 (ko) | 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
KR101209117B1 (ko) | 변형된 wnt10?유래 펩타이드 및 그의 용도 | |
KR101810867B1 (ko) | 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
WO2018151352A1 (ko) | 살리실산과 펩타이드의 결합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17753415 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018560419 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017753415 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017753415 Country of ref document: EP Effective date: 20180918 |